원료 사전 탐색/gluconolactone/GLUCONOLACTONE
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
합성 (Synthetic)

GLUCONOLACTONE

식약처 한글 표준명: 글루코노락톤
킬레이트제피부컨디셔닝제
[식약처 공정서 기원 및 정의] 이 원료는 다음의 구조를 갖는 락톤이다.
[EU CosIng Official Definition] D-Glucono-1,5-lactone
결론 선행 Executive Regulatory & Safety Fact BoxAEO / GEO CITATION ANCHOR

화장품에서 글루코노락톤 (GLUCONOLACTONE)의 글로벌 배합 한도와 핵심 효능·처방 기준은 무엇인가요?

글루코노락톤(표준 INCI: GLUCONOLACTONE, CAS 번호: 90-80-2)은 화장품 처방에서 주로 킬레이트제, 피부컨디셔닝제 목적으로 배합되는 핵심 원료입니다. 한국 식약처(미규제) 및 유럽 CosIng(미규제) 등 6대 권역 법정 기준 하에 관리되며, 통상 1–10%(적정 pH 3.6–4.8) 범위에서 안정적으로 처방됩니다.

7대 갈래 국가별·용도별 공식 전성분 라벨 표기명 매트릭스

각국 1차 법원 고시 정본 · 기계번역·임의 음차 0건
7-Track Official Statutory Label Names for GLUCONOLACTONE
국가·규제 트랙공식 고시 전성분 표기명원클릭 복사
① 한국 (MFDS 화장품 한글 표준명)글루코노락톤
② 한국 구명칭 (개정 전 이력 · 301 리다이렉트)——
③ 유럽 (EU CosIng EC 1223/2009)GLUCONOLACTONE
④ 미국 일반화장품 (US PCPC / MoCRA INCI)GLUCONOLACTONE
⑤ 미국 OTC (FDA Active Ingredient Monograph)— (비-OTC 일반 화장품 원료)—
⑥ 중국 (NMPA IECIC 표준 중문명)葡糖酸内酯
⑦ 일본 일반화장품 / 의약부외품 (JCIA / MHLW)GLUCONOLACTONE (표준 INCI 기준 · 임의 가타카나 변환 배제)

Layer 1 — 글로벌 6대 권역 법정 배합 한도 및 규제 상태

Layer 1 Statutory Regulatory Limits Across 6 Regions for GLUCONOLACTONE
권역규제 상태배합 한도제한 조건 및 1차 법원 출처
한국 (MFDS)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
유럽 (CosIng)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
미국 (FDA/CIR)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
중국 (NMPA)등재·허용GMPIECIC Entry #5123
일본 (MHLW)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
아세안 (ACD)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)

Layer 2 — 독성·안전성 평가 한도 (US CIR · EU SCCS MoS≥100 · CN IECIC 최고역사사용량)

「SCCS 안전 판정 상한」은 유럽 소비자안전과학위원회가 안전역(MoS≥100)으로 판정한 상한이며, 「CIR 시판 보고 농도」와 「중국 IECIC 최고역사사용량」은 실제 시판 제품에 보고된 최대 농도입니다.

Layer 2 Toxicological & Historical Safe Use Concentrations for GLUCONOLACTONE
안전성 평가 기준적용 부위·유형안전 농도 범위판정 결과 및 문헌 번호
중국 IECIC 최고역사사용량leave_on≤ 10%안전 판정(MoS≥100)NMPA IECIC (2025) Entry 05082 (2025)
중국 IECIC 최고역사사용량rinse_off≤ 6%안전 판정(MoS≥100)NMPA IECIC (2025) Entry 05082 (2025)
⚠️ 참조용 안내 (법적 면책 공지): 이 사전의 성분명·규제 한도·배합 가이드는 연구·개발 참조용으로만 제공됩니다. 각국 고시 개정 시차나 데이터 오기·누락이 있을 수 있으므로, 실제 제품 처방·라벨 표기·인허가 전에는 반드시 관할 기관(식약처 등)의 최신 공식 고시 원문을 직접 확인하시기 바라며, 본 사전의 정보를 잘못 사용하여 발생하는 문제에 대해 운영 주체는 법적 책임을 지지 않습니다.
제형군별 사분위수(Min–Q1–Median–Q3–Max) 분포 그래프

Layer 3 제형군별 통상 배합 농도(%) 레인지 & Layer 1 법정 한도 대조

수성 토너·세럼·앰플n=42
Min 1% · Q1 2% · Median 4% · Q3 6% · Max 10%
수성 토너·세럼·앰플 — 다가 수산기(-OH) 보유 차세대 폴리하이드록시애씨드(PHA) — 무자극 데일리 각질 정돈, 보습 및 금속이온 킬레이팅 항산화
공식 검증 원천: Jungbunzlauer Gluconolactone TDS & PubMed PHA Clinical Studies (cir_safety) · Jungbunzlauer · NeoStrata · K-Beauty
권장 중앙값: 4%

Layer 3 — 제형군별 통상 배합 농도(n≥5 사분위수) & 물리화학·상용성 가이드

Layer 3 Formulation Concentration Quartiles by Product Category for GLUCONOLACTONE
제형군 분류Min – Q1 – Median – Q3 – Max (%)처방 역할 및 기전Source ID
제형군 A — 수성 토너 · 세럼 · 고농축 앰플1% · 2% · 4% · 6% · 10%다가 수산기(-OH) 보유 차세대 폴리하이드록시애씨드(PHA) — 무자극 데일리 각질 정돈, 보습 및 금속이온 킬레이팅 항산화Jungbunzlauer Gluconolactone TDS & PubMed PHA Clinical Studies
피부 투과 과학 시각화 (Bos & Meinardi 500 Dalton Rule)MW: 178.14 Da · LogP: -1.98

각질층 장벽 투과 깊이 & 바이오 스피큘 경피전달(DDS) 시뮬레이션

각질층 (Stratum Corneum · 10~20 µm)500 Dalton 장벽 (고분자·친수성 성분 차단)생존 표피층 (Viable Epidermis · 50~100 µm)멜라닌세포 · 각질형성세포 타깃 (미백·장벽·턴오버)진피 유두층 (Papillary Dermis · 150~300 µm)섬유아세포 콜라겐 I/III · 엘라스틴 · PDRN 재생 타깃표피~상부 진피 확산 (<500 Da)
분자량(MW) & 친유성(LogP) 투과 판정
저분자 영역 (178.14 Da ≤ 500 Da) — 각질층 수동 확산 가능

단독 도포 시 각질층 세포간 지질(Brick & Mortar) 경로를 통해 확산됩니다. 500 Dalton 이상 친수성 분자는 각질층 표면에 주로 머물러 보습·보호막 역할을 수행합니다.

예상 도달 깊이
40–90 µm
권장 전달 시스템
Polyol Enhancer / Serum
계면화학 · pH · 열역학 공정 시각화

pH 안정성 스펙트럼(0~14) · 가열 한계 게이지 · HLB 콜로이드 상거동

Freely soluble in water (~59 g/100mL)
적정 처방 pH 안전 윈도우 (pH 0 ~ 14 스펙트럼)pH 3.6 – 4.8
0245.5791114

권장 구간 밖(pH < 3.6 또는 pH > 4.8)에서는 가수분해·점도 저하·이온 탈리 위험이 증가합니다.

공정 가열 한계 온도 (Max Process Temp)≤ 70°C
25°C45°C60°C75°C85°C100°C

최대 70°C 가열 공정에서 열적 안정성이 유지됩니다.

계면활성·유화 HLB 스펙트럼 (0 ~ 20) & 미셀/액정 배열 시뮬레이터
O/W 수중유형 미셀 에멀전 (수분 크림·로션)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
생화학 신호전달 경로 (Biochemical Pathway Map)

세포·분자 타깃 작용 기전 플로우 다이어그램

1. 각질층·표피 작용→ 촉진·활성 (Activation)
각질층 세포간 지질 & 수분 결합 네트워크
→
경피수분손실(TEWL) 억제 및 피부결 개선
2. 염증 매개체 조절⊣ 억제·차단 (Inhibition)
외부 자극 유도 산화 스트레스(ROS) 및 사이토카인
⊣
피부 진정 및 항상성 유지
처방 온톨로지 네트워크 그래프

권장 시너지(🟢 실선) & 배합 금기·주의(🔴 점선) 인터랙티브 관계도

+ LACTOBIONIC ACID+ SALICYLIC ACID+ ARGININE+ SODIUM CITRATE+ POLYACRYLATE CROSS…✕ ⚠️ 치명적 제형 사고 (경시적 pH…✕ 해결책: 가온 수상에서 미리 가수분해…GLUCONOLACTONE
노드 인터랙션 가이드

🟢 초록색 시너지 원료 노드를 클릭하면 해당 원료 모노그래프로 즉시 이동하며, 🔴 붉은색 점선 노드를 클릭하면 화학적 상충(석출·변색·실활) 메커니즘을 표시합니다.

대표 상용명 참고 (상표법 제90조 제1항 제2호 설명적 표기)
Jungbunzlauer Gluconolactone USP/FCC

상용명 표기는 상표법 제90조 제1항 제2호에 의거하여 연구원에게 원료 등급·규격을 설명하기 위한 참고용이며, 각 상표의 권리는 해당 원료사에 귀속됩니다.

학술·독성·제형 종합 요약 (Tier 1~3 탄력 요약)

Tier 1 Synthesis

이 원료에 매칭된 PubMed 동료심사 논문 초록과 공인 독성 보고서만으로 작성된 학술 요약입니다.

■ [1. 화학적 정체성 및 규격 (Chemical Identity & Standard Nomenclature)] - 표준명: 글루코노락톤 | INCI: GLUCONOLACTONE | CAS No.: 90-80-2 | EC No.: 202-016-5 - 기원 및 분류: SYNTHETIC | 주요 기능: 킬레이트제, 피부컨디셔닝제 - 물리화학 스펙: 분자식 C6H10O6 | 분자량 178.14 g/mol | LogP -1.98 | 이온성: anionic | PubChem CID 7027 - 7대 권역 공식 라벨 표기: KR [글루코노락톤] · EU [GLUCONOLACTONE] · US [GLUCONOLACTONE] · CN [葡糖酸内酯] · JP [-] · JP의약부외품 [-] ■ [2. 피부과학적 작용 기전 및 제형 내 역할 (Mechanism of Action & Function)] - 포도당의 산화 유도체인 고리형 에스테르(Polyhydroxy Acid, PHA)로, 물과 피부에서 글루콘산(Gluconic Acid)으로 가수분해되며 분자 내 4개의 수산기(-OH)를 보유합니다. 기존 글라이콜릭애씨드(AHA) 대비 분자량(178.14 Da)이 커서 각질층 침투가 완만하여 신경 자극(따가움·작열감)이 없으며, 강력한 보습능·금속 이온 킬레이팅 항산화능·광노화 방어 효과를 동시에 제공합니다. ■ [3. 글로벌 6대 권역 법정 규제 및 안전성 한도 (Layer 1 & Layer 2 Regulatory Matrix)] - 6개국 요약: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (중국 IECIC(2025) 등재번호 5123 (葡糖酸内酯)) - 6대 주요 권역(KR·EU·US·CN·JP·ASEAN) 별도 배합금지/특수제한 고시 없음 (GMP 일반 안전 기준 내 배합 허용). - 공인 안전성·역사적 사용 농도(Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): 최대 10.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): 최대 6.0% ■ [4. 제형군별 통상 배합 가이드 (Layer 3-A Formulation Dosage Guide)] - [aqueous_serum] 권장 범위: 1.0 ~ 10.0% (중앙값 4.0%, 근거: Jungbunzlauer Gluconolactone TDS & PubMed PHA Clinical Studies) — 다가 수산기(-OH) 보유 차세대 폴리하이드록시애씨드(PHA) — 무자극 데일리 각질 정돈, 보습 및 금속이온 킬레이팅 항산화 ■ [5. 연구원 공정 설계 · 안정성 · 배합 금기 (Layer 3-B Process & Compatibility)] - 투입 공정(Phase): Water Phase (Account for gradual hydrolysis into Gluconic Acid — buffer with Sodium Citrate / Arginine / NaOH) - 적정 pH 구간: pH 3.6 ~ 4.8 | 공정 내열 온도: 최대 70°C | 전해질(염) 내성: NONE - 배합 주의/금기: ⚠️ 치명적 제형 사고 (경시적 pH 급락 / pH Drift): 글루코노락톤 분말은 투입 직후에는 중성이지만, 물 속에서 수일~수주에 걸쳐 락톤 고리가 가수분해되어 글루콘산(Gluconic Acid, pKa 3.86)으로 변하면서 초기 pH 4.8이던 제품이 보관 중 pH 3.0 이하로 급락하고 유화·점도가 파괴됨! - 배합 주의/금기: 해결책: 가온 수상에서 미리 가수분해 평형에 도달시킨 뒤 알칼리(Arginine/NaOH/Sodium Citrate)로 목표 pH(3.8~4.5)로 완충(Buffering)하고, 점증제는 내산·내염성 SEPIMAX ZEN + Xanthan Gum을 사용할 것 - 시너지 추천 원료: LACTOBIONIC ACID, SALICYLIC ACID, ARGININE, SODIUM CITRATE, POLYACRYLATE CROSSPOLYMER-6 | 참고 상용 원료명: Jungbunzlauer Gluconolactone USP/FCC ■ [6. 학술 논문 및 공인 문헌 근거 (Peer-Reviewed Literature & Compendia)] - PMID 42249663 (2026, Int J Toxicol): Safety Assessment of Glycolactones as Used in Cosmetics - PMID 41668671 (2026, Int J Cosmet Sci): The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolacton - PMID 41215631 (2026, Adv Healthc Mater): Versatile Hyaluronic Acid Hydrogels via pH-Induced Gelation for Multifaceted Cutaneous Wound Healing

근거 동료심사 학술 논문 (미국 NIH PubMed) (12)

Safety Assessment of Glycolactones as Used in Cosmetics [PMID: 42249663 · 2026]
Ferguson P, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Peterson LA, Rettie AE, Ross D, Shank RC, Slaga TJ, Snyder PW, Tilton SC, Fiume MM, Heldreth B · Int J Toxicol (2026)

The Expert Panel for Cosmetic Ingredient Safety (Panel) assessed the safety of 5 glycolactone ingredients. Glucoheptonolactone and Gluconolactone are reported to function in cosmetics as skin-conditioning agents-miscellaneous, and Gluconolactone is also reported to function as a chelating agent. No functions are reported for the other 3 ingredients. The Panel considered the available data and concluded that Gluconolactone is safe in cosmetics in the present practices of use and concentration described in this safety assessment; however, the Panel concluded the available data are insufficient to make a determination that Galactonolactone, Glucarolactone, Glucoheptonolactone, and Ribonolactone are safe under the intended conditions of use in cosmetic formulations.

The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies [PMID: 41668671 · 2026]
Zhu M, He X, Zhu Z, Lynch S, Wang H, Zhou X, Tu Y, Steel A, Hsu KC, Niu Y, Cho A, Hashimoto M, Yan X, Su M, Wang W · Int J Cosmet Sci (2026)

This study aimed to explore the anti-skin aging efficacy of a novel serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract through one ex-vivo study and two clinical studies. In ex-vivo study, skin samples were exposed to the serum (Formula 1) and its active ingredient combinations (Formula 2). Biomarkers including matrix metalloproteinase-1, elastic fibres and collagen types I, III, IV and XVII content were analyzed to evaluate the efficacy. In clinical study 1 (n&#x2009;=&#x2009;50), the Formula 1's efficacy in reducing static wrinkles and improving skin quality was examined, while study 2 (n&#x2009;=&#x2009;42) focused on its efficacy against dynamic wrinkles. Formula 1 significantly increased levels of anti-aging biomarkers including elastic fibres, collagen fibres, etc. Meanwhile, Formula 1 significantly improved static wrinkle appearance within the first week, with mean clinical scoring from 35% to 69% for various types of wrinkles after 12&#x2009;weeks of use (all&#xa0;p&#x2009;&lt;&#x2009;0.001). The clinical scoring for dynamic wrinkles improved by 10%-13% (all p&#x2009;&lt;&#x2009;0.001). Additionally, significant improvements were observed in skin quality, indicated by clinical scoring changes of smoothness (30%), radiance (27%), skin pore (43%), elasticity (33%) and firmness (36%) (all p&#x2009;&lt;&#x2009;0.001). The serum demonstrates significant anti-aging effects, effectively improving static and dynamic wrinkles and skin quality. cette &#xe9;tude visait &#xe0; &#xe9;tudier l'efficacit&#xe9; sur la peau d'un nouveau s&#xe9;rum anti&#x2010;&#xe2;ge contenant de l'hexapeptide ac&#xe9;tyl&#x2010;8, du dipeptide diaminobutyroyl benzylamide diac&#xe9;tate, de la gluconolactone, de la niacinamide et de l'extrait de laminaire dans le cadre d'une &#xe9;tude ex&#x2010;vivo ainsi que de deux &#xe9;tudes cliniques. M&#xc9;THODES: dans une &#xe9;tude ex&#x2010;vivo, des &#xe9;chantillons de peau ont &#xe9;t&#xe9; expos&#xe9;s au s&#xe9;rum (Formule 1) et &#xe0; ses associations de principes actifs (Formule 2). Des analyses des biomarqueurs, notamment de la m&#xe9;talloprot&#xe9;inase&#x2010;1 matricielle, des fibres &#xe9;lastiques et des collag&#xe8;nes de type I, III, IV et XVII, ont permis d'&#xe9;valuer l'efficacit&#xe9;. Dans l'&#xe9;tude clinique 1 (n&#x2009;=&#x2009;50), l'efficacit&#xe9; de la Formule 1 dans la r&#xe9;duction des rides statiques et l'am&#xe9;lioration de la qualit&#xe9; de la peau a &#xe9;t&#xe9; examin&#xe9;e, alors que l'&#xe9;tude 2 (n&#x2009;=&#x2009;42) portait sur son efficacit&#xe9; contre les rides dynamiques. R&#xc9;SULTATS: la Formule 1 a significativement augment&#xe9; les taux de biomarqueurs anti&#x2010;&#xe2;ges, y compris les fibres &#xe9;lastiques, les fibres de collag&#xe8;ne, etc. Qui plus est, la Formule 1 a significativement am&#xe9;lior&#xe9; l'aspect des rides statiques au cours de la premi&#xe8;re semaine, le score clinique moyen &#xe9;tant de 35% &#xe0; 69% pour diff&#xe9;rents types de rides apr&#xe8;s 12 semaines d'utilisation (p&#x2009;&lt;&#x2009;0,001 pour tous). Le score clinique pour les rides dynamiques s'est am&#xe9;lior&#xe9; de 10 &#xe0; 13% (p &lt;&#x2009;0,001 pour toutes). En outre, des am&#xe9;liorations significatives ont &#xe9;t&#xe9; observ&#xe9;es au niveau de la qualit&#xe9; de la peau, indiqu&#xe9;es par des changements de notation clinique de la douceur (30%), de l'&#xe9;clat (27%), des pores cutan&#xe9;s (43%), de l'&#xe9;lasticit&#xe9; (33%) et de la fermet&#xe9; (36%) (p&#x2009;&lt;&#x2009;0,001 pour toutes). le s&#xe9;rum a d&#xe9;montr&#xe9; des effets anti&#x2010;&#xe2;ges significatifs en am&#xe9;liorant efficacement les rides statiques et dynamiques ainsi que la qualit&#xe9; de la peau.

Versatile Hyaluronic Acid Hydrogels via pH-Induced Gelation for Multifaceted Cutaneous Wound Healing [PMID: 41215631 · 2026]
Yang X, Wu K, Liu Y, Liu Y, Fu Y, Lin W, Mao Z, Wang X, Guo H · Adv Healthc Mater (2026)

Hyaluronic acid (HA) hydrogels have attracted growing interest for&#xa0;skin regeneration. However, conventional fabrication approaches for HA hydrogels often require complex chemical modifications, leading to prolonged preparation cycles, inconsistent batch reproducibility, and elevated toxicity. Herein, a straightforward strategy is presented for developing pure yet multifunctional HA hydrogels by regulating the pH. Specifically, highly concentrated HA solutions are initially prepared at high pH, followed by gradual neutralization mediated by the hydrolysis of gluconolactone (GdL). This pH-triggered process promotes the reformation of intermolecular hydrogen bonds, thereby culminating in a sol-to-gel transition. Owing to this unique formation mechanism, the HA-GdL (HG) hydrogels exhibit strong adhesiveness, desirable mechanical toughness, and excellent self-healing properties. Moreover, these dynamic interactions provide the HG hydrogels with injectability, moldability, and 3D printability, enabling the incorporation of therapeutic agents under physiologically benign conditions. In murine-infected wound models, silver nanoparticle-laden HG hydrogels not only conform to the irregular shape of the wounds but also exert anti-bacterial, anti-inflammatory, pro-angiogenic, and immunoregulatory effects to expedite wound closure and regeneration. Collectively, this study offers a streamlined yet highly efficient approach for fabricating versatile HA hydrogel dressings, offering significant promise for the comprehensive management of infected wounds.

Simultaneous determination of sodium hyaluronate and gluconolactone in cosmetic products [PMID: 40525233 · 2025]
Shetty S, Mehta R, Choudhury RP · Int J Cosmet Sci (2025)

The increasing prevalence of sodium hyaluronate and gluconolactone in a wide range of cosmetic formulations has created a crucial need for robust and reliable analytical methods to ensure product quality, optimize formulations and meet regulatory standards. Sodium hyaluronate and gluconolactone, two highly sought-after humectants renowned for their remarkable water-binding properties, present significant analytical challenges during quantification. Sodium hyaluronate, a complex polymeric structure, lacks a UV-absorbing chromophore and gluconolactone needs an indirect technique (derivatization/conversion to gluconic acid) to be quantified, which makes these analyses quite challenging in cosmetic products. This study directly addresses this critical gap in cosmetic analysis by developing and validating a novel method for the simultaneous determination of sodium hyaluronate and gluconolactone in cosmetic compositions. This method employs size exclusion liquid chromatography (SEC), a powerful separation technique ideal for analysing polymers and macromolecules, coupled with sensitive UV detection. Using a BioSep SEC S2000 column and an isocratic mobile phase of 0.05&#x2009;M potassium dihydrogen phosphate (pH&#x2009;7.0), we achieved efficient separation and detection at 205&#x2009;nm, enabling the quantification of both compounds despite the absence of strong chromophores. Rigorous method validation confirmed the reliability and robustness of this approach. The method demonstrated excellent linearity (r 2 &#x2009;&gt;&#x2009;0.999) over a wide concentration range of 25-1000&#x2009;&#x3bc;g/mL for both sodium hyaluronate and gluconolactone, ensuring accurate quantification across diverse formulation concentrations. Additionally, high precision (RSD &#x2264;1.22%), specificity against common cosmetic excipients and satisfactory recovery rates (80%-120%) further validate the method's suitability for routine quality control analysis in the cosmetic industry. This sensitive, accurate and robust SEC-UV method provides a valuable new tool for cosmetic manufacturers to ensure the quality, efficacy and consumer safety of products containing these key ingredients. La pr&#xe9;valence croissante de l&#x2019;hyaluronate de sodium et de la gluconolactone dans un large &#xe9;ventail de formulations cosm&#xe9;tiques a g&#xe9;n&#xe9;r&#xe9; un besoin crucial de m&#xe9;thodes analytiques robustes et fiables pour garantir la qualit&#xe9; du produit, optimiser les formulations et respecter les normes r&#xe9;glementaires. Le hyaluronate de sodium et la gluconolactone, deux humectants tr&#xe8;s recherch&#xe9;s reconnus pour leurs remarquables propri&#xe9;t&#xe9;s de liaison &#xe0; l&#x2019;eau, pr&#xe9;sentent des d&#xe9;fis analytiques significatifs pendant la quantification. Le hyaluronate de sodium, une structure polym&#xe9;rique complexe, ne dispose pas d&#x2019;un chromophore absorbant les UV et la gluconolactone n&#xe9;cessite une technique indirecte (d&#xe9;rivatisation/conversion vers l&#x2019;acide gluconique) pour &#xea;tre quantifi&#xe9;e, ce qui rend ces analyses assez difficiles dans les produits cosm&#xe9;tiques. M&#xc9;THODE: cette &#xe9;tude traite directement cette lacune critique dans l&#x2019;analyse cosm&#xe9;tique en d&#xe9;veloppant et en validant une nouvelle m&#xe9;thode pour la d&#xe9;termination simultan&#xe9;e du hyaluronate de sodium et de la gluconolactone dans les compositions cosm&#xe9;tiques. Cette m&#xe9;thode utilise la chromatographie en phase liquide d&#x2019;exclusion st&#xe9;rique (SEC), une technique de s&#xe9;paration puissante id&#xe9;ale pour analyser les polym&#xe8;res et les macromol&#xe9;cules, associ&#xe9;e &#xe0; une d&#xe9;tection UV sensible. En utilisant une colonne BioSep SEC S2000 et une phase mobile isocratique de dihydrog&#xe9;nophosphate de potassium 0,05 M (pH 7,0), nous avons obtenu une s&#xe9;paration et une d&#xe9;tection efficaces &#xe0; 205 nm, permettant la quantification des deux compos&#x

Comparison of Efficacy and Willingness to a 5% Gluconolactone-Based Topical Serum and Intense Pulsed Light in Mild Erythema of Rosacea: A Paired Control Study [PMID: 40111222 · 2025]
Peng Y, Mao M, Huang Z, Zhao H, Li Y, Jian D · J Cosmet Dermatol (2025)

Mild erythema is a common affliction of rosacea. Many methods including drugs and phototherapy (e.g., Intense Pulse Light, IPL) have been tried to alleviate symptoms. Topical applications for enhancing moisturization have also been thought to be of some benefit. In this study, the improvement of erythema and skin physiology parameters were assessed after a topical serum (5% gluconolactone-based serum) usage or a single IPL treatment, and the differences in improvement between the two groups were compared. The treatment willingness of the subjects was also performed. In this study, 200 subjects with mild erythema were enrolled; 100 of them were treated with topical serum (TS) for 30 consecutive days and the other 100 for a single IPL treatment. Facial images, local skin images, and physiological measurements were collected before and after treatment, to assess erythema (CEA), overall facial condition (VAS), and other skin physiology parameters (e.g., pore, skin tone, and sebum). Based on the questionnaire, the treatment willingness and satisfaction of the subjects were collected. Improvement on erythema, overall facial condition, and skin physiology parameters were observed in two groups. Both subjective assessments and measurements showed greater efficacy in erythema reduction, overall facial condition improvement, and sebum reduction in the IPL group (p&#x2009;&lt;&#x2009;0.05). Pores and skin tone improvement were comparable in TS and IPL groups. Similarly, subjects with certain erythema improvement in both groups were satisfied with their choice of treatment, in which possible side effects, cost, and duration of the treatment somewhat influence their treatment decisions. Topical serum that focuses on redness reduction and moisturization and IPL can improve erythema and skin physiological indicators. IPL is more capable of improving the overall facial appearance. By fully understanding the patient's facial condition and treatment influence, medical practitioners determine the appropriate treatment. ClinicalTrials.gov identifier: ChiCTR2400087665.

Development and Characterization of Biocompatible Chitosan-Aloe Vera Films Functionalized with Gluconolactone and Sorbitol for Advanced Wound Healing Applications [PMID: 39999379 · 2025]
Kaczmarek-Szczepa&#x144;ska B, Glajc P, Chmielniak D, Gwizdalska K, Swiontek Brzezinska M, Dembi&#x144;ska K, Shinde AH, Gierszewska M, &#x141;ukowicz K, Basta-Kaim A, D'Amora U, Zasada L · ACS Appl Mater Interfaces (2025)

Chitosan (CTS) has emerged as a promising biopolymer for wound healing due to its biocompatibility, biodegradability, and intrinsic bioactive properties. This study explores the development and characterization of CTS-based films enhanced with natural bioactive agents, aloe vera (A), gluconolactone (GL), and sorbitol (S), to improve their mechanical, antimicrobial, and regenerative performance for potential use in advanced wound care. A series of CTS-based films were fabricated with varying concentrations of A, GL, and S, and their physicochemical, mechanical, and biological properties were comprehensively evaluated. Fourier transform infrared (FTIR) spectroscopy and atomic force microscopy (AFM) analysis revealed modifications in the film structure attributable to these additives, influencing the surface roughness, hydrophilicity, and thermal stability. Biocidal assays confirmed enhanced antimicrobial activity, particularly in films containing GL and A. Biodegradation studies demonstrated a significant enhancement in microbial decomposition of the films, while cytocompatibility tests confirmed minimal cytotoxic effects and improved cellular response. This research underscores the potential of combining CS with A, GL, and S to engineer multifunctional biomaterials tailored for effectively tackling different phases of the wound healing process, offering a sustainable and biocompatible alternative for clinical applications.

Gluconolactone restores immune regulation and alleviates skin inflammation in lupus-prone mice and in patients with cutaneous lupus [PMID: 39970231 · 2025]
Li W, Kolios AGA, Pan W, Burbano C, Karino K, Vichos T, Humbel M, Kyttaris VC, Tsokos MG, Tsokos GC · Sci Transl Med (2025)

Systemic lupus erythematosus (SLE) is characterized by dysfunctional regulatory T cells (T regs ). We previously showed that protein phosphatase 2A (PP2A) plays a critical role in maintaining the suppressive function of T regs . Here, we analyzed phosphoproteomics and metabolomics data from PP2A-wild type and PP2A-deficient T regs and demonstrated that PP2A regulates T reg function through the pentose phosphate pathway (PPP). Furthermore, we proved that the PPP metabolite gluconolactone (GDL) enhances in vitro induced (i)T reg differentiation and function by promoting forkhead box protein 3 and phosphorylated signal transducer and activator of transcription 5 expression and inhibits T helper 17 (T H 17) differentiation in murine cells. In short-term imiquimod-induced autoimmunity in mice, treatment with GDL alleviates inflammation by inhibiting T H 17 cells. GDL promotes T regs function and alleviates skin lesions in MRL. lpr lupus-prone mice in vivo. It also promotes T regs differentiation and function in ex vivo experiments using cells from patients with SLE. Last, in patients suffering from cutaneous lupus erythematosus, topical application of a GDL-containing cream controlled skin inflammation and improved the clinical and histologic appearance of the skin lesions within 2 weeks. Together, we have identified GDL as a PPP metabolite and showed mechanistically that it restores immune regulation in vitro and in vivo by inducing T reg suppressive function and inhibiting T H 17 cells. GDL should be considered as a treatment approach for inflammatory and autoimmune diseases.

Bioactivation of Konjac Glucomannan Films by Tannic Acid and Gluconolactone Addition [PMID: 39163280 · 2024]
Kaczmarek-Szczepa&#x144;ska B, Zasada L, D'Amora U, Pa&#x142;ubicka A, Michno A, Ronowska A, Wekwejt M · ACS Appl Mater Interfaces (2024)

Wound healing is a dynamic process that requires an optimal extracellular environment, as well as an accurate synchronization between various cell types. Over the past few years, great efforts have been devoted to developing novel approaches for treating and managing burn injuries, sepsis, and chronic or accidental skin injuries. Multifunctional smart-polymer-based dressings represent a promising approach to support natural healing and address several problems plaguing partially healed injuries, including severe inflammation, scarring, and wound infection. Naturally derived compounds offer unique advantages such as minimal toxicity, cost-effectiveness, and outstanding biocompatibility along with potential anti-inflammatory and antimicrobial activity. Herein, the main driving idea of the work was the design and development of konjac glucomannan d-glucono-1,5-lactone (KG) films bioactivated by tannic acid and d-glucono-1,5-lactone (GL) addition. Our analysis, using attenuated total reflectance-Fourier transform infrared, atomic force microscopy, and surface energy measurements demonstrated that tannic acid (TA) clearly interacted with the KG matrix, acting as its cross-linker, whereas GL was embedded within the polymer structure. All developed films maintained a moist environment, which represents a pivotal property for wound dressing. Hemocompatibility experiments showed that all tested films exhibited no hemolytic impact on human erythrocytes. Moreover, the presence of TA and GL enhanced the metabolic and energetic activity in human dermal fibroblasts, as indicated by the MTT assay, showing results exceeding 150%. Finally, all films demonstrated high antibacterial properties as they significantly reduced the multiplication rate of both Staphylococcus aureus and Escherichia coli in bacterial broth and created the inhibition zones for S. aureus in agar plates. These remarkable outcomes make the KG/TA/GL film promising candidates for wound healing applications.

Split-face evaluation: Gluconolactone plus oxybrasion versus gluconolactone plus microneedling. The effects on skin parameters [PMID: 37357656 · 2023]
Jarz&#x105;bek-Perz S, Dziedzic M, Ko&#x142;odziejczak A, Rotsztejn H · Skin Res Technol (2023)

The application of polyhydroxy acids and alpha-hydroxy acids to the skin is often used in cosmetology. To enhance the effect of gluconolactone chemical peeling, a combined method including water-oxygen oxybrasion or microneedle mesotherapy can be used. To evaluate skin parameters such as hydration, sebum, pH and TEWL after application of a 10% gluconolactone chemical peel in combination with oxybrasion and microneedling. Twenty-one Caucasian women participated in the study. A series of three split face treatments was carried out at 1-week intervals. Oxybrasion was performed on the right side of the face and micro-needle mesotherapy on the left side. A 10% gluconolactone solution was applied to the entire face. Before the first and third treatments and 2 weeks after the last treatment, skin parameters were evaluated. Photographic documentation was also made before and after the treatment series. Evaluation of skin parameters using Courage &amp; Khazaka 580 Multi Probe Adapter probes (Courage + Khazaka electronic GmbH, Cologne, Germany) showed an increase in hydration and a decrease in sebum, pH and TEWL for both treatments. There were no statistically significant differences between the treatments. Combining chemical peeling of gluconolactone with oxybrasion and microneedle mesotherapy is a good method to seal the hydrolipid barrier and increase skin hydration.

Metabolomic differences between exanthematous drug eruption and infectious mononucleosis [PMID: 39387831 · 2024]
Liu Y, Guan Q, Liu L, et al. · Skin Res Technol (2024)

Exanthematous drug eruption and infectious mononucleosis (IM) are both exanthematous diseases. Current research on exanthematous drug eruption and IM mainly targets identifying these disorders, the resulting differences at the metabolism level have not yet been systematically analyzed. A total of 30 cases of exanthematous drug eruption and IM, 10 patients without exanthema and 10 healthy volunteers were enrolled, 3&#xa0;mL of fasting venous blood was collected, the serum metabolite content was detected by gas chromatography-mass spectrometry metabolomics. A total of 165 metabolites were identified, exhibiting significant differences in plasma metabolic trends between exanthematous drug eruption and IM, and pinpointed 28 potential biomarkers. Notable changes were seen in the metabolic activities of the pentose phosphate pathway (PPP), tricarboxylic acid cycle (TCA-cycle), and galactose metabolism, characterized by increased levels of gluconate, gluconolactone, glucose, galactaric acid, and mannose, along with decreased amounts of pyruvic acid, succinic acid, malic acid, and glycerol, indicating an impairment in the exanthematous drug eruption group's capacity to endure oxidative stress and regulate energy metabolism. In contrast to its medication without rash counterpart, the exanthematous drug eruption group's plasma displayed distinct metabolic routes, predominantly in the processing of arginine and proline, along with the TCA. This resulted in a marked reduction in urea levels and a rise in pyruvate, citrate, and ornithine, indicating hypoxic stress as the primary cause of these rashes. In contrast to the healthy control group, the IM group showed 26 potential biomarkers, marked by increased levels of ketoglutaric acid, malic acid, pyruvic acid, and oxoglutaric acid, and reduced amounts of glutamine, galacturonic acid, arachidonic acid, trimethylphosphonic acid ester, gluconolactone, and indole acetic acid. Mainly, the metabolic pathways included the TCA, breaking down alanine, aspartate and glutamate metabolism, and the processing of D-glutamine and D-glutamate metabolism, underscoring the body's crucial role in generating energy and inflammatory agents through the citric acid cycle. The comparison of serum metabolomic features of exanthematous drug eruptions and IM outlines a unique pattern closely related to the differences in the pathogenesis of these two exanthematous diseases.

Injectable bone cement based on magnesium potassium phosphate and cross-linked alginate hydrogel designed for minimally invasive orthopedic procedures [PMID: 39217204 · 2024]
Wekwejt M, Jesiołkiewicz R, Mielewczyk-Gryń A, et al. · Sci Rep (2024)

Bone cement based on magnesium phosphate has extremely favorable properties for its application as a bioactive bone substitute. However, further improvement is still expected due to difficult injectability and high brittleness. This paper reported the preparation of novel biocomposite cement, classified as dual-setting, obtained through ceramic hydration reaction and polymer cross-linking. Cement was composed of magnesium potassium phosphate and sodium alginate cross-linked with calcium carbonate and gluconolactone. The properties of the obtained composite material and the influence of sodium alginate modification on cement reaction were investigated. Our results indicated that proposed cements have several advantages compared to ceramic cement, like shortened curing time, diverse microstructure, increased wettability and biodegradability and improved paste cohesion and injectability. The magnesium phosphate cement with 1.50% sodium alginate obtained using a powder-to-liquid ratio of 2.5&#xa0;g/mL and cross-linking ratio 90/120 of GDL/CC showed the most favorable properties, with no adverse effect on mechanical strength and osteoblasts cytocompatibility. Overall, our research suggested that this novel cement might have promising medical application prospects, especially in minimally invasive procedures.

Formulation of Ascorbic Acid and Betaine-based Therapeutic Deep Eutectic System for Enhanced Transdermal Delivery of Ascorbic Acid [PMID: 38794349 · 2024]
Song JE, Jun SH, Ryoo JY, et al. · Pharmaceutics (2024)

L-ascorbic acid (AA), a potent antioxidant, is commonly used topically in the pharmaceutical and cosmetic fields. However, the incorporation of AA into topical formulations is difficult because of its highly unstable nature and relatively poor skin permeability. In this study, we propose an alternative strategy for improving the solubility and topical delivery of AA through its conversion to a therapeutic deep eutectic system (THEDES). AA and betaine (Bet)-based THEDESs were prepared at certain molar ratios and characterized using polarized optical microscopy, Fourier transform infrared spectroscopy, and differential scanning calorimetry. Solubility tests showed that AA in the form of THEDES was readily soluble in various polyols (glycerin, 1,3-butylene glycol, dipropylene glycol, and 1,3-propanediol) at a high concentration (approximately 40%). Furthermore, compared to AA alone or the physical mixture of AA and Bet, AA-based THEDES significantly enhanced AA delivery through porcine skin. In an in vivo human study, THEDES-containing serum reduced the markers of aging and induced an even skin tone. These findings indicate the utility of AA and Bet-based THEDES as novel transdermal delivery systems for AA. Furthermore, our approach also showed good extension to developing gluconolactone, a well-known natural antioxidant, and Bet-based THEDES, showing potential application in transdermal delivery systems.

자주 묻는 질문 (AEO 스니펫 최적화 FAQ)

Q1. 글루코노락톤 (GLUCONOLACTONE)의 국가별 공식 전성분 표기명은 어떻게 다른가요?
한국 식약처 표준명은 '글루코노락톤', 미국 PCPC 및 유럽 CosIng INCI 표기는 'GLUCONOLACTONE', 중국 NMPA IECIC 표준명은 '葡糖酸内酯', 일본 화장품 표시명칭은 'GLUCONOLACTONE'입니다.
Q2. 글루코노락톤의 글로벌 6대 권역 법정 배합 한도(Layer 1)는 무엇인가요?
한국(KR: none), 유럽(EU: none), 미국(US: none), 중국(CN: allowed), 일본(JP: none), 아세안(ASEAN: none) 고시 기준을 준수하여 처방해야 합니다.
Q3. 제형 설계 시 글루코노락톤의 통상 배합 농도(Layer 3)와 적정 pH는 얼마인가요?
대표 제형군(aqueous_serum) 기준 통상 1~10%(권장 중앙값 4%) 범위로 투입하며, 적정 pH는 3.6~4.8입니다.
Q4. 글루코노락톤 배합 시 주의해야 할 상용성 금기(Incompatibilities)와 시너지 성분은 무엇인가요?
주요 권장 시너지 조합은 LACTOBIONIC ACID, SALICYLIC ACID, ARGININE, SODIUM CITRATE, POLYACRYLATE CROSSPOLYMER-6이며, 배합 주의사항은 ⚠️ 치명적 제형 사고 (경시적 pH 급락 / pH Drift): 글루코노락톤 분말은 투입 직후에는 중성이지만, 물 속에서 수일~수주에 걸쳐 락톤 고리가 가수분해되어 글루콘산(Gluconic Acid, pKa 3.86)으로 변하면서 초기 pH 4.8이던 제품이 보관 중 pH 3.0 이하로 급락하고 유화·점도가 파괴됨!; 해결책: 가온 수상에서 미리 가수분해 평형에 도달시킨 뒤 알칼리(Arginine/NaOH/Sodium Citrate)로 목표 pH(3.8~4.5)로 완충(Buffering)하고, 점증제는 내산·내염성 SEPIMAX ZEN + Xanthan Gum을 사용할 것입니다.